Thermo Fisher opens Gothenburg bioanalytical and biomarker lab to boost European capacity

Thermo Fisher Scientific said on May 18 that it opened a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, adding capacity in Europe for pharmaceutical and biotechnology clients running drug-development programs. The facility is part of the company’s PPD clinical research business and is linked to Thermo Fisher’s global bioanalytical network, according to the company. It is located in GoCo Health Innovation City, a life-sciences cluster in Gothenburg. Thermo Fisher said the lab will support customers across all phases of drug development. (ppd.com) (investors.nuvationbio.com) The opening adds to a services push inside Thermo Fisher’s pharma services and clinical research operations rather than its instrument business. The company said the Gothenburg site is designed to deliver full-service bioanalytical and biomarker solutions and to help customers move therapies through development faster. Thermo Fisher’s Sweden careers page describes the GoCo laboratory as a 2,694-square-meter facility. ### Why did Thermo Fisher put this lab in Gothenburg? GoCo Health Innovation City in Gothenburg is the specific site Thermo Fisher named for the new laboratory. (ppd.com) In its announcement, the company said the location will connect into its global network and expand support for complex modalities across all phases of drug development. Thermo Fisher has also been hiring senior assay-services leadership in Gothenburg, according to a company job posting tied to immunochemistry and chromatographic sciences at GoCo. Sweden is already part of Thermo Fisher’s broader Nordic footprint. (ppd.com) The company’s Sweden page says Gothenburg also hosts a warehouse and office serving laboratory equipment and consumables customers across the Nordics, alongside the new bioanalytical lab. ### What work is the new lab expected to do? Thermo Fisher said the Gothenburg facility will provide bioanalytical and biomarker services for pharmaceutical and biotechnology customers. The company described the site as supporting complex modalities, though the announcement did not list a full menu of assays or named client programs at launch. (ppd.com) Thermo Fisher’s framing places the site inside outsourced drug-development services. Its investor materials and annual reporting describe pharmaceutical services as part of a broader strategy that combines clinical research, manufacturing and laboratory capabilities for biopharma customers. (jobs.thermofisher.com) ### How does Nuvation Bio fit into the Thermo Fisher story? Nuvation Bio said on May 13 that it would collaborate with Thermo Fisher Scientific for U.S.-based manufacturing of IBTROZI, its treatment for ROS1-positive non-small cell lung cancer. The company said it had completed a technology transfer and product introduction to Thermo Fisher for final drug-product manufacturing in the United States. (ppd.com) Jennifer Cannon, president of commercial operations for pharma services at Thermo Fisher, said in that release that Nuvation had selected the company for final drug-product manufacturing of IBTROZI in the United States. That manufacturing agreement is separate from the Gothenburg lab opening, but it shows Thermo Fisher adding work across multiple outsourced biopharma services lines in the same month. (sec.gov) ### What does this add to Thermo Fisher’s broader services network? Thermo Fisher’s May 18 release said the Gothenburg laboratory expands the company’s global bioanalytical capabilities. (investors.nuvationbio.com) The PPD clinical research business has been one of the main brands through which Thermo Fisher sells outsourced clinical development and laboratory services to drugmakers. On May 20, Thermo Fisher also used its 2026 investor day to highlight growth outlook and long-term value creation, according to its newsroom. The Gothenburg opening came two days earlier, giving the company a fresh example of capacity expansion in front of investors and customers following that presentation. (prnewswire.com) ### What happens next? May 18 is the formal opening date Thermo Fisher gave for the Gothenburg laboratory, and the company said the site is now part of its operating bioanalytical network. For Nuvation Bio, the next disclosed milestone is manufacturing support for IBTROZI in the United States under the collaboration announced May 13. (ppd.com) (newsroom.thermofisher.com)